Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

451.38 -1.98 (-0.44%)

Streaming Delayed Price Updated: 12:31 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

69 70 Next >

Nike To $70? Here Are 10 Top Analyst Forecasts For Tuesday ↗

May 06, 2025

Via Benzinga

Rising Costs Weigh on Vertex Q1 Earnings ↗

May 06, 2025

Via The Motley Fool

Topics Intellectual Property

Wondering what's happening in today's S&P500 pre-market session? ↗

May 06, 2025

Discover the top S&P500 movers in Tuesday's pre-market session and stay informed about market dynamics.

Via Chartmill

Ichor Holdings Posts Weak Earnings, Joins Fabrinet, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

May 06, 2025

Via Benzinga

Earnings Scheduled For May 5, 2025 ↗

May 05, 2025

Via Benzinga

Earnings Outlook For Vertex Pharmaceuticals ↗

May 02, 2025

Via Benzinga

This Vertex Pharmaceuticals Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday ↗

May 06, 2025

Via Benzinga

Vertex Pharma Stock’s Retail Buzz Intensifies As 2025 Revenue View Lift Fails To Offset Q1 Miss ↗

May 05, 2025

The company’s Q1 revenue missed expectations, but the company raised its 2025 revenue guidance, reflecting optimism about growth drivers like cystic fibrosis treatments and its expanding pipeline.

Via Stocktwits

Topics World Trade

Monday's after hours session: top gainers and losers in the S&P500 index ↗

May 05, 2025

Let's have a look at what is happening on the US markets after the closing bell on Monday. Below you can find the top S&P500 gainers and losers in today's after hours session.

Via Chartmill

Vertex Pharmaceuticals Stock Falls On Q1 Earnings, Revenue Miss — Company Raises Low End Of FY25 Revenue Guidance ↗

May 05, 2025

Vertex Pharmaceuticals reports first-quarter financial results after the market close on Monday. Here's a look at the key highlights from the period.

Via Benzinga

Vertex Pharmaceuticals (NASDAQ:VRTX) Reports Sales Below Analyst Estimates In Q1 Earnings

May 05, 2025

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 3% year on year to $2.77 billion. The company’s full-year revenue guidance of...

Via StockStory

Vertex Reports First Quarter 2025 Financial Results

May 05, 2025

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Has Lost Some Sizzle Into Q1 Earnings - Can Alyftrek, Journavx Reignite The Momentum? ↗

May 05, 2025

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reports Q1 earnings with $4.32 EPS and $2.85B revenue. Stock up 25.48% in past year, charts show bullish trend.

Via Benzinga

Stocks Pause Gains As Treasury Yields Rise: What's Driving Markets Monday? ↗

May 05, 2025

Wall Street kicked off the week with a cautious tone, as major stock indices hovered near the flatline by midday in New York. Investors digested fresh signs of inflationary pressure in the services...

Via Benzinga

Vertex Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗

May 05, 2025

Via Benzinga

Stock Market Selloff: 4 No-Brainer Stocks to Buy Right Now ↗

May 05, 2025

Now may be a smart time to buy small stakes in these fundamentally robust companies.

Via The Motley Fool

Topics Artificial Intelligence Economy

3 No-Brainer Stocks to Buy in May ↗

May 05, 2025

Via The Motley Fool

5 Growth Stocks to Buy in May and Go Away ↗

May 04, 2025

Via The Motley Fool

Topics Artificial Intelligence Government World Trade

Earnings To Watch: Vertex Pharmaceuticals (VRTX) Reports Q1 Results Tomorrow

May 04, 2025

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing earnings results tomorrow afternoon. Here’s what investors should know.

Via StockStory

Topics Artificial Intelligence

S&P Global, Berkshire Hathaway, CME Group And A Health Care Stock: CNBC's 'Final Trades' ↗

May 01, 2025

Via Benzinga

Topics Stocks

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Shows Strong Technical Breakout Potential ↗

April 30, 2025

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Shows Strong Technical Breakout Potential

Via Chartmill

These 3 Funds Offer Sky-High Yields of 15% or More and Trade at a Discount ↗

April 30, 2025

Via The Motley Fool

$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today ↗

April 29, 2025

Via Benzinga

Large Cap Biopharmaceutical Update: Mixed Performance As Tariffs Loom ↗

April 28, 2025

Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising...

Via Talk Markets

Topics ETFs Stocks / Equities

My 5 Top Stocks to Buy Right Now in This Highly Volatile Market ↗

April 28, 2025

Via The Motley Fool

Topics Artificial Intelligence Energy

Why Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday ↗

April 22, 2025

Via The Motley Fool

3 Relatively Safe Healthcare Growth Stocks You Can Buy and Hold ↗

April 22, 2025

Via The Motley Fool

Topics Government

Expert Outlook: Vertex Pharmaceuticals Through The Eyes Of 18 Analysts ↗

April 22, 2025

Via Benzinga

Fed Chairman Jerome Powell Warns Trump's Tariffs Could Cause Stagflation: 3 Stocks to Buy and Hold if He's Right ↗

April 22, 2025

Via The Motley Fool

Topics Economy Government World Trade

Vertex Has A Lot Riding On Alyftrek, Journavx — And Investors Are Watching Closely ↗

April 21, 2025

Vertex Pharmaceuticals is expected to report first quarter earnings on May 5, with investor focus on its two big launches and potential upside surprises.

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

69 70 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.